Waverley Waves Goodbye To Generics As It Relinquishes ANDAs
Bortezomib And Pemetrexed ANDAs Transferred Back To Reliance Life Sciences
Executive Summary
Waverley Pharma has blamed deep discounting and heavy competition for its decision to step back from generics and focus entirely on novel drug development.